GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stryker Corp (NYSE:SYK) » Definitions » Capex-to-Revenue

SYK (Stryker) Capex-to-Revenue : 0.03 (As of Sep. 2024)


View and export this data going back to 1988. Start your Free Trial

What is Stryker Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Stryker's Capital Expenditure for the three months ended in Sep. 2024 was $-170.00 Mil. Its Revenue for the three months ended in Sep. 2024 was $5,494.00 Mil.

Hence, Stryker's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.03.


Stryker Capex-to-Revenue Historical Data

The historical data trend for Stryker's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stryker Capex-to-Revenue Chart

Stryker Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.03 0.03 0.03 0.03

Stryker Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.03

Competitive Comparison of Stryker's Capex-to-Revenue

For the Medical Devices subindustry, Stryker's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stryker's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stryker's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Stryker's Capex-to-Revenue falls into.



Stryker Capex-to-Revenue Calculation

Stryker's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-575) / 20498
=0.03

Stryker's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-170) / 5494
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stryker  (NYSE:SYK) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Stryker Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Stryker's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Stryker Business Description

Address
1941 Stryker Way, Portage, MI, USA, 49002
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
Executives
Spencer S Stiles officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Kevin Lobo officer: Group Pres., Neurotech & Spine STRYKER, 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Ronda E Stryker director 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
M Kathryn Fink officer: VP, Global Human Resources 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Viju Menon officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Glenn S Boehnlein officer: Vice President, CFO 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Robert S Fletcher officer: VP, Chief Legal Officer 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Berry William E Jr officer: Vice President, Controller 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Allan C. Golston director 2825 AIRVIEW BLVD., KALAMAZOO MI 49002
Srikant Datar director ICF INTERNATIONAL, INC., 9300 LEE HIGHWAY, FAIRFAX VA 22031
James Andrew Pierce officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Giovanni Caforio director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Timothy J Scannell officer: Group President 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Roch Doliveux director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Katherine Ann Owen officer: VP 2825 AIRVIEW BLVD., KALAMAZOO MI 49002